The only exception is the use of pyridoxine, the precursor of pyridoxal phosphate, which is an essential cofactor of AGT, for the treatment of PH1 patients with mutations leading to mitochondrial mislocalization of AGT, mostly the p.Gly170Arg mutation [69,70]. The gene discussed is AGT; the disease is primary hyperoxaluria type 1.